Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

Patent metadata

Field	Value
Publication number	US-11529372-B1
Application number	US-202217817281-A
Country	US
Kind code	B1
Filing date	Aug 3, 2022
Priority date	Mar 29, 2017
Publication date	Dec 20, 2022
Grant date	Dec 20, 2022

Abstract

The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

First claim

What is claimed is:

1. A method of expanding tumor infiltrating lymphocytes (TILs) into a therapeutic population of TILs, the method comprising:
(a) performing a first expansion by (i) thawing cryopreserved dissociated tumor materials comprising a first population of TILs from a tumor that was resected from a subject with cancer, dissociated after the resection, and cryopreserved after the dissociation, and (ii) culturing the first population of TILs in a cell culture medium comprising IL-2 to produce a second population of TILs, wherein the first expansion is performed in a closed container providing a first gas-permeable surface area, wherein the first expansion is performed for a first period of about 3 to 11 days to obtain the second population of TILs;
(b) performing a second expansion by supplementing the cell culture medium with additional IL-2, OKT-3, and antigen presenting cells (APCs) to produce a third population of TILs, wherein the second expansion is performed for a second period of about 7 to 11 days to obtain the third population of TILs, wherein the third population of TILs is a therapeutic population of TILs, wherein the second expansion is performed in a closed container providing a second gas-permeable surface area, and wherein the transition from step (a) to step (b) occurs without opening the system; and
(c) harvesting the third population of TILs obtained from step (b), wherein the transition from step (b) to step (c) occurs without opening the system.

2. The method according to claim 1 , further comprising:
(d) transferring the harvested third TIL population from step (c) to an infusion bag, wherein the transfer from step (c) to (d) occurs without opening the system.

3. The method according to claim 2 , further comprising:
(e) cryopreserving the infusion bag comprising the harvested TIL population from step (d) using a cryopreservation process.

4. The method according to claim 3 , further comprising:
(f) administering a therapeutically effective dosage of the harvested TIL population from the infusion bag in step (e) to the subject.

5. The method according to claim 1 , wherein the dissociated tumor materials comprise a tumor digest.

6. The method according to claim 1 , wherein the dissociated tumor materials comprise one or more tumor fragments.

7. The method according to claim 1 , wherein obtaining the dissociated tumor materials comprises mechanically disrupting the tumor resected from the subject.

8. The method according to claim 1 , wherein obtaining the dissociated tumor materials comprises enzymatically disrupting the tumor resected from the subject.

9. The method according to claim 4 , wherein the third population of TILs harvested in step (c) comprises sufficient TILs for administering a therapeutically effective dosage of the TILs in step (f).

10. The method according to claim 9 , wherein the therapeutically effective dosage in step (f) comprises from about 1×10 9 to about 9×10 10 TILs.

11. The method according to claim 9 , wherein the therapeutically effective dosage in step (f) comprises from about 1×10 9 to about 5×10 9 TILs.

12. The method according to claim 9 , wherein the therapeutically effective dosage in step (f) comprises from about 5×10 9 to about 1×10 10 TILs.

13. The method according to claim 9 , wherein the therapeutically effective dosage in step (f) comprises from about 1×10 10 to about 5×10 10 TILs.

14. The method according to claim 1 , wherein the APCs comprise peripheral blood mononuclear cells (PBMCs).

15. The method according to claim 14 , wherein the PBMCs are supplemented at a ratio of about 1:25 TIL:PBMCs.

16. The method according to claim 1 , wherein the therapeutic population of TILs harvested in step (c) exhibits an increased subpopulation of CD8+ cells relative to the first and/or second population of TILs.

17. The method according to claim 1 , wherein the first expansion in step (a) and the second expansion in step (b) are each individually performed within a period of 11 days.

18. The method according to claim 1 , wherein steps (a) through (c) are performed in about 10 days to about 22 days.

19. The method according to claim 1 , wherein steps (a) through (c) are performed in about 15 days to about 22 days.

20. The method according to claim 1 , wherein steps (a) through (c) are performed in about 20 days to about 22 days.

21. The method according to claim 1 , wherein the closed container in step (a) and/or step (b) is a gas-permeable bag.

22. The method according to claim 1 , wherein the cancer is selected from the group consisting of melanoma (including metastatic melanoma), ovarian cancer, cervical cancer, non-small-cell lung cancer (NSCLC), lung cancer, bladder cancer, breast cancer, cancer caused by human papilloma virus, head and neck cancer (including head and neck squamous cell carcinoma (HNSCC)), renal cancer, and renal cell carcinoma.

23. The method according to claim 1 , wherein the cancer is a melanoma.

Assignees

• Iovance Biotherapeutics Inc

Inventors

• Wardell Seth
• Bender James
• Lotze Michael T

Classifications

• C12N2501/603

  Oct-3/4 · CPC title

• C12N2501/2321

  Interleukin-21 (IL-21) · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• C12N2501/2302

  Interleukin-2 (IL-2) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title